Vincenzi Antonella, Cesana Francesca, Cirò Antonio, Garatti Laura, Achilli Felice
Heart Failure Unit, Cardiology Department,San Gerardo Hospital, Monza, Italy.
Cardiology. 2017;138 Suppl 1:13-16. doi: 10.1159/000484877. Epub 2017 Dec 21.
Patients with advanced heart failure (HF) experience a continuous decline in quality of life and have a very poor prognosis. Moreover, due to numerous comorbidities present in these patients, transplantation and left ventricular assist devices are usually impracticable in clinical practice. In this challenging setting, administration of inotropic agents may be the only possible therapy; however, this treatment requires frequent hospitalizations. Our hypothesis is that sacubitril/valsartan, given its marked efficacy and manageability, can be safely used in clinical practice in this setting, potentially reducing hospitalizations and the need for inotropic support. We report here our experience in a small series of patients with advanced HF treated with sacubitril/valsartan.
晚期心力衰竭(HF)患者的生活质量持续下降,预后极差。此外,由于这些患者存在多种合并症,在临床实践中,移植和左心室辅助装置通常不可行。在这种具有挑战性的情况下,使用正性肌力药物可能是唯一可行的治疗方法;然而,这种治疗需要频繁住院。我们的假设是,沙库巴曲/缬沙坦因其显著的疗效和可管理性,可在这种情况下安全地用于临床实践,有可能减少住院次数和对正性肌力支持的需求。我们在此报告我们在一小系列接受沙库巴曲/缬沙坦治疗的晚期HF患者中的经验。